NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
86 trialsNCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT02572843 2025-10-28
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
Phase 2 Completed
NCT03801902 2025-09-23
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
National Cancer Institute (NCI)
Phase 1 Completed
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT03085225 2025-09-04
TRAMUNE
Institut Bergonié
Phase 1 Completed
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02087423 2025-04-27
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT04003246 2025-03-21
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02879162 2025-03-07
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Completed
NCT04249362 2025-01-10
DUART
AstraZeneca
Phase 2 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04712903 2025-01-07
CANTABRICO
AstraZeneca
Phase 3 Completed
NCT04078152 2024-12-20
WAVE
AstraZeneca
Phase 4 Completed
NCT03702179 2024-12-05
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT04449861 2024-11-27
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
AstraZeneca
Phase 3 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT04416633 2024-11-08
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
AstraZeneca
Phase 4 Completed
NCT03204812 2024-10-15
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03435107 2024-10-15
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center
Phase 2 Completed
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03822351 2024-10-08
COAST
MedImmune LLC
Phase 2 Completed
NCT02454933 2024-09-19
CAURAL
AstraZeneca
Phase 3 Completed
NCT02492867 2024-09-03
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT04385368 2024-08-30
MERMAID-1
AstraZeneca
Phase 3 Completed
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT03830866 2024-07-26
CALLA
AstraZeneca
Phase 3 Completed
NCT04642469 2024-06-25
MERMAID-2
AstraZeneca
Phase 3 Completed
NCT03094286 2024-06-24
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
Phase 2 Completed
NCT03693300 2024-06-18
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT03132467 2024-06-05
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT04089553 2024-04-16
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
AstraZeneca
Phase 2 Completed
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02879617 2024-01-05
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Academic Thoracic Oncology Medical Investigators Consortium
Phase 2 Completed
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02527434 2023-11-15
Study of Tremelimumab in Patients With Advanced Solid Tumors
AstraZeneca
Phase 2 Completed
NCT03206073 2023-10-24
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02718911 2023-10-16
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT02904954 2023-10-11
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT02125461 2023-10-10
PACIFIC
AstraZeneca
Phase 3 Completed
NCT02685826 2023-10-06
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed